The European Commission has approved the use of the CF therapy Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
Site Search
Showing 441 - 450 of 591 results
News
|
Oct. 19, 2012
|
3 min read
News
|
July 27, 2012
|
1 min read
News
|
Oct. 23, 2012
|
3 min read
News
|
Oct. 22, 2012
|
2 min read
The U.S. Food and Drug Administration (FDA) announced that it has approved Ultresa™ delayed-release capsules, a pancreatic enzyme replacement therapy. Ultresa (pancrelipase) is manufactured by Aptalis Pharma.
News
|
March 2, 2012
|
1 min read
News
|
Aug. 31, 2012
|
2 min read
The European Medicines Agency (EMA) announced today that it has recommended the approval of the CF drug Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
News
|
May 25, 2012
|
2 min read
News
|
Oct. 25, 2012
|
2 min read
News
|
April 19, 2012
|
3 min read
News
|
Dec. 21, 2012
|
3 min read